Short answer
LENZ Therapeutics, Inc. (LENZ) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces LENZ Therapeutics’ financial results for the quarter ended June 30, 2026.
LENZ Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces LENZ Therapeutics’ financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary
- Results announcement dated August 11, 2026, providing investors the latest operating and financial update
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $5.5M, including $1.7M product sales and $3.8M license revenue
- VIZZ volume reached approximately 27,000 packs, up 9% sequentially, supporting early commercial traction
- Over 60% of ePharmacy patients repurchased, with Q4 2025 and Q1 2026 cohorts tracking to five packs annually
- SG&A rose to $39.4M as launch investments drove Q2 net loss to $31.9M, or $1.02 per share
- Cash, equivalents and marketable securities totaled $220.0M, while international partnerships added milestone and royalty opportunities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LENZ Therapeutics, Inc. 8-K filings
Get the next LENZ 8-K as it lands
Follow LENZ for push alerts, or ask the research agent what this filing means.